An unexpected role for cyclin E-CDK2 in regulating responses to cancer immunotherapy

IF 16 1区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Cell Pub Date : 2026-10-01 DOI:10.1016/j.molcel.2026.09.005

René Bernards

引用次数: 0

Abstract

In this issue of Molecular Cell, Chu et al.1 describe that cancers with increased cyclin E-CDK2 activity suppress responses to immunotherapy through phosphorylation of BRD4, resulting in downregulation of interferon-stimulated genes. Their findings suggest approaches to enhance immunotherapy responses.

查看原文本刊更多论文

细胞周期蛋白E-CDK2在调节癌症免疫治疗反应中的意外作用

在这一期的Molecular Cell中，Chu等人1描述了周期蛋白E-CDK2活性增加的癌症通过磷酸化BRD4抑制对免疫治疗的反应，导致干扰素刺激基因的下调。他们的发现提出了增强免疫治疗反应的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Cell 生物-生化与分子生物学

CiteScore

26.00

自引率

3.80%

发文量

389

审稿时长

1 months

期刊介绍： Molecular Cell is a companion to Cell, the leading journal of biology and the highest-impact journal in the world. Launched in December 1997 and published monthly. Molecular Cell is dedicated to publishing cutting-edge research in molecular biology, focusing on fundamental cellular processes. The journal encompasses a wide range of topics, including DNA replication, recombination, and repair; Chromatin biology and genome organization; Transcription; RNA processing and decay; Non-coding RNA function; Translation; Protein folding, modification, and quality control; Signal transduction pathways; Cell cycle and checkpoints; Cell death; Autophagy; Metabolism.